limit updat follow earlier pre-announce thesi
unchang market headwind persist maintain neutral
follow earlier pre-announce januari
offer limit addit inform quarter result
origin light revenu y/i miss origin btig/consensu
estim respect offer color
guidanc call product revenu growth year
guidanc includ modest contribut recent launch
custom hip underli knee growth expect return
launch ident knee system cementless version
sale expect slightli improv lsd msd balanc
year new countri introduct take hold management note growth
expect similar would impli anoth declin put lot
expect later part year depend aetna
rate revers polici built guidanc management assum
headwind stem portion busi persist launch
ident itot hip highli success year progress
believ new product launch success certainti given
on-go challeng market continu remain sidelin
market dynam continu nag underli product growth management note
on-go dynam includ aetna case denial gener physician interest
cementless option robot trial ou reimburs headwind
specif within germani sourc challeng management note littl chang
prevail forc expect launch new product
particularli drive factor sale growth improv
itot hip full market releas hip system gener revenu
y/i key bright spot process activ
train new surgeon estim surgeon limit
launch new management goal track toward number full
launch time
cfo bob howe take helm appoint bob howe cfo along
key leadership posit mr howe join nxstage medic
vice-president financ corpor control along previou role lake region
medic analyst thibault buy pt
expect similar term product revenu growth
bulk declin itot cr/uni/duo itot ps expect
meaning return growth itot cr/uni/duo busi expect
itot ps turn year progress specif within new
product roll
valuat rate neutral risk discuss
idc btig estim compani document
million except per share amount
like technolog includ new itot hip believ offer distinct clinic advantag
physician experi enough benefit compel switch brand sever challeng still ahead
worsen payor dynam feel inexpens valuat alon enough make limit
upsid share view
full launch itot ident
limit launch cementless knee
throughout full launch itot hip
throughout on-going commerci licens deal
base case call revenu sale growth
low end guid rang assum gm in-lin
guid
upsid share would seen improv insur coverag
reimburs obtain us allow faster expect
revenu growth knee implant portfolio upsid could seen
faster expect uptak new product
addit issu insur coverag reimburs would see
deterior revenu slower growth lead consider downsid
share slower expect uptak new product greater expect
cash burn would also lead downsid
medic technolog
compani use proprietari ifit
image-to-impl technolog
develop manufactur sell joint
replac implant
shape size fit
massachusett base compani
public sinc june
commerci sinc
began iuni knee
expand cruciat retain
total knee itot cr
recent posterior
stabil knee itot ps
futur market may
includ hip extrem spine
report revenu y/i xfx miss btig consensu estim
y/i y/i product revenu came y/i xfx y/i
estim iuni/iduo/cr revenu came y/i in-lin estim y/i itot ps
y/i y/i estim itot hip revenu came y/i
estim
gm quarter in-lin expect percentag total revenu
compar estim call respect told
lp came versu estim
made follow chang model
revenu lower expect forecast fall in-lin guidanc account on-going
headwind within busi particular slow us growth come in-lin guid growth rate
actualsbtig estimate variancetot bpsproduct bpsitot bpsitot bpss spend bpsg spend bpsr spend bpsebit marginnmnmnmtax ratenmnmnmsourc btig research estim compani filingsvari
 increas expect gm slightli increas forecast expens also initi
estim
rate neutral continu view line product possess clinic valu
payor issu neg impact revenu sizabl challeng ahead see limit upsid share despit
inexpens valuat btig publish price target neutral-r stock risk rate upsid includ
rapid reimburs decis aetna rapid uptak knee implant acceler adopt itot
hip greater expect expens reduct downsid risk includ worsen payor dynam competit
shift robot within orthoped gross margin improv materi share dilut
marginnmnmnmnmnmnmn/an/an/asourc btig research estim compani filingsnewold chang
incom etot y/i sale time oper incom incom tax expens net incom share oper expens btig research estim compani report
revenu product product product revenuesourc btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
